Drug Approval | January 20, 2022
VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
First launches expected in H1 2022
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Subscribe To Our Newsletter & Stay Updated
